REFERENCES
[1] Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults
with congenital heart disease. Circulation. 2007 Feb 27;115(8):1039-50.
doi:10.1161/CIRCULATIONAHA.105.592386
[2] Jiang Q, Zhang W, Hu R, et al. Outcomes of Surgical
Reimplantation for Anomalous Origin of One Pulmonary Artery From the
Aorta. Ann Thorac Surg. 2021 Apr;111(4):1351-1357.
doi:10.1016/j.athoracsur.2020.07.023
[3] Mondoni M, Carlucci P, Cipolla G, et al. Long-term prognostic
outcomes in patients with haemoptysis. Respir Res. 2021 Aug 4;22(1):219.
doi:10.1186/s12931-021-01809-6
[4] Baroutidou A, Arvanitaki A, Hatzidakis A, et al. Haemoptysis in
Pulmonary Arterial Hypertension Associated with Congenital Heart
Disease: Insights on Pathophysiology, Diagnosis and Management. J Clin
Med. 2022 Jan 26;11(3):633.
doi:10.3390/jcm11030633
[5] Cantu J, Wang D, Safdar Z. Clinical implications of haemoptysis
in patients with pulmonary arterial hypertension. Int J Clin Pract
Suppl. 2012 Oct;(177):5-12.
doi:10.1111/ijcp.12004
[6] Tsai YS, Hsu LW, Wu MS, Chen KH, Kang YN. Effects of Tranexamic
Acid on Hemoptysis: A Systematic Review and Meta-Analysis of Randomized
Controlled Trials. Clin Drug Investig. 2020 Sep;40(9):789-797.
doi:10.1007/s40261-020-00946-y
[7] Haskal ZJ. SIR 2005 Annual Meeting Film Panel Case: hemoptysis
and bronchial artery embolization in an adult with uncorrected truncus
arteriosus and Eisenmenger syndrome. J Vasc Interv Radiol. 2005
May;16(5):635-8.
doi:10.1097/01.RVI.0000161372.87971.84
[8] Greaves K, Bye P, Parker G, Celermajer DS. Prevalence of
haemoptysis in adults with pulmonary atresia and ventricular septal
defect, and the role of mammary artery collateral vessels.Heart.2003 Aug; 89(8): 937–938.
doi:10.1136/heart.89.8.937
[9] Gagnon S, Quigley N, Dutau H, Delage A, Fortin M. Approach to
Hemoptysis in the Modern Era.Can
Respir J. 2017 Dec 21. doi:10.1155/2017/1565030
[10] Ketai LH, Mohammed TLH, Krisch J, et al. ACR appropriateness
criteria® hemoptysis. J Thorac Imaging. 2014 May;29(3):W19-22.
doi:10.1097/RTI.0000000000000084
[11] Castñer E, Gallardo X, Rimola J, et al. Congenital and acquired
pulmonary artery anomalies in the adult: radiologic overview.
Radiographics. 2006 Mar-Apr;26(2):349-71.
doi:10.1148/rg.262055092
[12] Yu S, Yarnell JWG, Sweetnam PM, Murray L. What level of
physical activity protects against premature cardiovascular death? The
Caerphilly study. Heart. 2003 May;89(5):502-6.
doi:10.1136/heart.89.5.502
[13] Madras SA, Mehta HS, Vaidya A. Pulmonary Hypertension: A Brief
Guide for Clinicians. Mayo Clin Proc. 2020 Sep;95(9):1978-1988.
doi:10.1016/j.mayocp.2020.04.039
[14] Ascha M, Renapurkar RD, Tonelli AR. A review of imaging
modalities in pulmonary hypertension. Ann Thorac Med. 2017
Apr-Jun;12(2):61-73.
doi:10.4103/1817-1737.203742
[15] Galiè N, Brundage BH, Ghofrani HA, et al. Pulmonary Arterial
Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil
therapy for pulmonary arterial hypertension. Circulation.2009;119:2894–2903.
doi:10.1161/CIRCULATIONAHA.108.839274
[16] Odiz RJ, Brundage BH, Galiè N, et al. Tadalafil for the
Treatment of Pulmonary Arterial Hypertension: A Double-Blind 52-Week
Uncontrolled Extension Study. J Am Coll Cardiol. 2012;60(8):768-774.
doi:10.1016/j.jacc.2012.05.004
[17] Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB.
Cost-utility of treatments for pulmonary arterial hypertension: Markov
state-transition decision analysis model. Clin Drug Investig.2009;29(10):635–646.
doi:10.2165/11317820-000000000-00000